论文部分内容阅读
对４１例急性肝炎（下称急肝组）、５９例慢性活动性肝炎（下称慢活肝组）、２９例肝炎肝硬化（下称肝硬化组）及２例无症状ＨＢＶ携带者进行吲哚青绿（ＩＣＧ）试验，并与转氨酶（ＡＬＴ）、胆红素（ＢＩＬ）试验和血白蛋白／球蛋白（Ａ／Ｇ）测定结果进行比较。结果显示，急肝、慢活肝、肝硬化及ＨＢＶ携带者的ＩＣＧ试验阳性率分别为５０％、８７．５％、１００％及０；ＩＣＧ平均滞留率分别为１２．３±７．７％、２０．６±９．３％、３７．１±１３．５％及５．５％。认为ＩＣＧ试验对诊断肝硬化最有价值，并可作为判断肝脏损害程度、疗效及估计预后的指标；其对急肝的诊断不如ＡＬＴ和ＢＩＬ试验敏感；对慢活肝的诊断价值与ＡＬＴ检测相近，但优于ＢＩＬ试验及Ａ／Ｇ比值测定。
41 cases of acute hepatitis (hereinafter referred to as acute liver disease), 59 cases of chronic active hepatitis (hereinafter referred to as chronic active liver group), 29 cases of hepatitis cirrhosis (hereinafter referred to as cirrhosis group) and 2 cases of asymptomatic HBV carriers were indole Indocyanine green (ICG) test and compared with the results of ALT, BIL and A / G assays. The results showed that the ICG test positive rates of acute liver, slow-living liver, cirrhosis and HBV carriers were 50%, 87.5%, 100% and 0 respectively; the average ICG retention rates were 12.3 ± 7.7% , 20.6 ± 9.3%, 37.1 ± 13.5% and 5.5% respectively. It is considered that ICG test is most valuable in diagnosing cirrhosis and can be used as an index to judge the degree of liver damage, curative effect and prognosis. It is less sensitive to the diagnosis of acute liver than ALT and BIL. The diagnostic value of slow-living liver is similar to that of ALT , But better than the BIL test and A / G ratio determination.